Immunogenicity - Google Patents
Group B Streptococcal Type II and IIIImmunogenicity
View PDF- Document ID
- 2144252626961122990
- Author
- Immunogenicity P
External Links
Snippet
Properties That Influence Immunogenicity Conjugate Vaccines: Physicochemical Group B
Streptococcal Type II and III Page 1 10.1128/CVI.00122-06. 2006, 13(8):936. DOI: Clin. Vaccine
Immunol. C. Fusco D'Ambra, Maryline Laude-Sharp, Samuel Moore and Peter Francis Michon …
- 150000004676 glycans 0 abstract description 91
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
- A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
- A61K47/4833—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0830380B1 (en) | Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2, 5-anhydro-d-mannose terminal structure and conjugate vaccine thereof | |
| KR102225282B1 (en) | Immunogenic composition comprising conjugated capsular saccharide antigen, kit comprising same, and use thereof | |
| KR101446238B1 (en) | Protein matrix vaccine and method for its preparation and vaccine administration method | |
| Paoletti et al. | Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. | |
| Paoletti et al. | Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine | |
| Laferrière et al. | The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity | |
| CA2142981C (en) | Vaccines against group c neisseria meningitidis | |
| KR20190103256A (en) | Polypeptide-antigen conjugates with unnatural amino acids | |
| CN111757754A (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| CN111757753A (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| JPH06340550A (en) | Modified oligosaccharide bonded-vaccine | |
| CN106102770A (en) | Comprise immunogenic composition of conjugated capsular CA and application thereof | |
| JP4163251B2 (en) | Group B Streptococcus Type II and Type V Polysaccharide-protein conjugate vaccine | |
| AU2005316864A1 (en) | Glycoconjugate vaccines containing peptidoglycan | |
| US5843461A (en) | Group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccines | |
| Michon et al. | Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity | |
| SK15122003A3 (en) | Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins | |
| Immunogenicity | Group B Streptococcal Type II and III | |
| Paoletti et al. | Group B Streptococcus type III glycoconjugate vaccines | |
| RU2818894C1 (en) | C-polysaccharide-free capsular polysaccharides of streptococcus pneumoniae with a 2,5-anhydromanose residue at the reducing end | |
| TW202444421A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| by Different | Group B | |
| WESSELS et al. | Group B Streptococcal Vaccines | |
| EA048093B1 (en) | PURIFIED CAPSULE POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAE | |
| Bryla et al. | Treatment with Succinic Anhydride |